Combinatorial Screening of Biscarbamate Ionizable Lipids Identifies a Low Reactogenicity Lipid for Lipid Nanoparticle mRNA Delivery

New publication to which our members, eTheRNA and University of Ghent contributed. This work paves the way for the design of mRNA vaccines to combat infectious diseases and cancers with enhanced efficacy and improved tolerability.


Messenger RNA (mRNA) has emerged as a promising therapeutic modality for various diseases. However, efficient delivery of mRNA into target cells remains a significant challenge. In this study, the combinatorial synthesis and characterization of a novel series of ionizable biscarbamate lipids (IBLs) for mRNA lipid nanoparticle (LNP) delivery are reported. A simplified and scalable method is developed, resulting in IBLs suitable for formulating mRNA into stable LNPs. Two generations of IBLs are synthesized and evaluated for their mRNA transfection capacity in vitro, using eGFP as a reporter protein, leading to the identification of S-Ac7-DOG as a lead IBL. Upon intramuscular vaccination, S-Ac7-DOG LNPs instigated robust antigen-specific CD8+ T cell responses against an mRNA encoded viral oncoprotein and a tumor neo-antigen. In comparison to MC3 LNPs, which are used as a benchmark, S-Ac7-DOG LNPs exhibit low reactogenicity, robust mRNA transfection, and a distinct biodistribution, with higher accumulation in draining lymph nodes and spleen. These findings highlight the potential of IBLs as a novel and promising class of ionizable lipids for mRNA delivery in vaccines and beyond.

You can read the complete paper here.